PGE selects ADVA’s assured PNT solution for critical smart grid infrastructure
18.8.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Portland General Electric (PGE) is deploying Oscilloquartz PTP grandmaster clock technology as it upgrades to packet-based synchronization and protects its network against GNSS vulnerabilities and cyberattacks, while conforming to PNT Executive Order 13905. PGE, one of the largest power utilities in the Western United States, is using ADVA scalable timing solution to not only enable a smooth transition from legacy synchronization and ensure new levels of accuracy, reliability and resiliency but also to timestamp data and control grid substations at the edge. With multi-band GNSS receivers and AI-powered threat detection, ADVA’s assured PNT (aPNT) platform helps maintain resilient timing, even in challenging circumstances such as deliberate jamming and spoofing attacks. Easy to install and operate, the solution also provides multi-source backup, including PTP network timing and in-device holdover oscillators for when GNSS signals are unavailable or disrupted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005033/en/
ADVA’s aPNT platform is key for the development of PGE’s critical network infrastructure (Photo: Business Wire)
“Precise and resilient synchronization is increasingly vital in the power industry. By harnessing new time-sensitive applications and building smarter energy infrastructure, we can offer even more to customers across our region. ADVA’s Oscilloquartz technology will be a key tool as we continue to lead the way to a more sustainable and affordable energy future for our community,” said John Lozano, senior telecommunications engineer, PGE. “ADVA’s OSA 5420 Series supports our existing synchronization services while also enabling packet time distribution all the way to the edge of our network. With its GPS jamming and spoofing detection, it provides a robust yet cost-efficient defense against cyber threats. It also makes maintenance and configuration simple with an easy-to-operate web GUI and customizable database.”
PGE’s new timing infrastructure will distribute stable and accurate frequency, phase and time-of-day information between its power infrastructure data points, including PMUs, IEDs and substation LAN IEC 61850 communications, supporting rapid decision-making and automated assurance. The solution is built on the OSA 5410 and OSA 5420 Series of edgeSync+™ grandmaster clocks. It features multi-band, multi-constellation GNSS receivers and supports multiple PTP profiles, including substation power and core telecom backup sync, while also allowing conversion between them and supporting legacy interfaces. The products are part of ADVA’s new aPNT platform, integrating threat detection, multi-source backup and ADVA’s intelligent Ensemble Sync Director, as the new trusted standard for PNT service assurance, control and visibility.
“We’re proud that PGE is leveraging our synchronization technology and the support of our team as it makes the shift to next-generation timing. With its compact and environmentally friendly design, our technology will bring assured and protected synchronization to the edge of PGE’s network, enhancing efficiency and enabling it to take advantage of emerging smart grid applications,” commented John Scherzinger, SVP, sales, Americas, ADVA. “PGE’s highly resilient new solution will deliver the nanosecond accuracy and the levels of timing availability required by tomorrow’s power utilities. It features aPNT capabilities, our centralized GNSS monitoring and assurance tool for predictive maintenance, and our multi-band receivers with the power to compensate for ionospheric delay variations and protect against GNSS vulnerabilities.”
Further information on ADVA’s aPNT platform is available in this sync guide: https://adva.li/apnt-sync-guide.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005033/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
